Inmune Bio, Inc. (INMB) FY2024 10-K Annual Report
Inmune Bio, Inc. (INMB) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 27, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Inmune Bio, Inc. FY2024 10-K Analysis
Business Overview
- • Core business: Develops innate immune system-targeted biologic therapies for cancer, neurodegenerative diseases, and rare pediatric disorders
- • NEW emphasis: Added CORDStrom stem cell product for recessive dystrophic epidermolysis bullosa (RDEB), pivotal trial complete, plans BLA filing in US 2025-2026
- • Strategic shift: Accelerated approval pathways targeted for cancer drug INKmune and Alzheimer’s drug XPro1595, orphan and rare pediatric designations leveraged
- • Notable metric: Global Phase II Alzheimer’s trial enrolled 208 patients; CORDStrom pivotal RDEB trial data to support marketing submissions in US, EU, UK in 2025-2026
- • Unusual fact: CORDStrom uniquely uses pooled human umbilical cord mesenchymal stem cells with proprietary manufacturing for consistent off-the-shelf cellular medicines
Management Discussion & Analysis
- • Net loss $42.1M FY2024 vs $30.0M FY2023; cash $20.9M FY2024 vs $35.8M FY2023, cash burn increasing
- • R&D expense $33.2M FY2024 vs $20.3M FY2023, driven by DN-TNF Alzheimer’s $23.8M and INKmune/CORDStrom $4.6M
- • Best segment: DN-TNF Alzheimer’s with $23.8M R&D spend; Worst: Other preclinical programs $0.6M, smallest investment
- • No dividends or buybacks; funded operations primarily by equity/debt; capex detail not disclosed, focusing on clinical/manufacturing
- • Clinical progress key risk: Phase II XPro AD results in June 2025; CORDStrom BLA filing expected late 2025/early 2026; ongoing significant losses cast doubt on going concern
Risk Factors
- • Regulatory risk FDA approval delays or non-approval; potential loss of priority or accelerated review, impacting time-to-market for product candidates
- • Macroeconomic risk capital depletion risk; cash $20.9M as of Dec 31, 2024 vs $35.8M in 2023 with $42.1M net loss in 2024 risking going concern status
- • Operational risk dependency on DN-TNF and INKmune platforms; failure of these platforms threatens core product pipeline and future development
- • Competitive risk competition from larger biotech/pharma with greater resources and earlier approved drugs; FDA exclusivity periods up to 3.5 years may hinder approval
- • Financial risk continuing losses with accumulated deficit $163.1M; need additional capital to fund ongoing operations and product development
Inmune Bio, Inc. FY2024 Key Financial MetricsXBRL
Revenue
$14,000
▼ -91.0% YoY
Net Income
-$42M
▼ -40.2% YoY
Operating Margin
-304535.7%
▼ -28534797bp YoY
Net Margin
-300585.7%
▼ -28122571bp YoY
ROE
-131.1%
▼ -5074bp YoY
Total Assets
$40M
▼ -30.6% YoY
EPS (Diluted)
$-2.11
▼ -26.3% YoY
Operating Cash Flow
-$33M
▼ -178.5% YoY
Source: XBRL data from Inmune Bio, Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Inmune Bio, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.